Introduction {#sec1-2048004019841971}
============

Atherosclerosis is a systemic disease that often affects arteries in more than one location. Polyvascular disease (PvD) (i.e. at least two major affected arterial beds), or multisite artery disease as referred to in recent guidelines^[@bibr1-2048004019841971],[@bibr2-2048004019841971]^ is associated with an increased risk for cardiovascular (CV) events, both short and long term.^[@bibr3-2048004019841971]^ PvD has been associated with an adverse prognosis also in patients who have suffered from an episode of acute coronary syndrome.^[@bibr3-2048004019841971],[@bibr4-2048004019841971]^

Peripheral artery disease (PAD), with manifestation of atherosclerotic disease predominately in the legs, has a rising global prevalence.^[@bibr5-2048004019841971]^ PAD is diagnosed as an ankle--brachial index (ABI) \< 0.9 (or \>1.4).^[@bibr6-2048004019841971]^ The majority of patients with PAD are asymptomatic.^[@bibr7-2048004019841971]^ Symptomatic patients, categorized in intermittent claudication or critical limb ischemia, as well as patients with asymptomatic PAD run an increased risk for CV event^[@bibr8-2048004019841971]^ and will benefit from most CV preventive strategies.^[@bibr9-2048004019841971]^ Although the evidence for antiplatelet treatment in patients with asymptomatic PAD is less clear,^[@bibr1-2048004019841971]^ the strict control of risk factors is the cornerstone of care. Therefore, it is important to assess patients with a high risk of PAD, even if they are asymptomatic, to detect clinically masked PAD.^[@bibr2-2048004019841971]^

The Walking Impairment Questionnaire (WIQ) was developed as a self-administered and self-reported instrument to assess patients with PAD and their ability related to walking distance, walking speed, and ability to climb stairs in the outpatient setting. WIQ is a validated correlate of objective walking ability^[@bibr10-2048004019841971][@bibr11-2048004019841971]--[@bibr12-2048004019841971]^ and is associated with the risk of future CV events;^[@bibr13-2048004019841971][@bibr14-2048004019841971][@bibr15-2048004019841971]--[@bibr16-2048004019841971]^ however, there is no published study evaluating WIQ in a population with recent myocardial infarction (MI).

The aims of this present study were to examine in a cohort of patients with recent MI: whether WIQ is a useful clinical tool to identify MI patients with PAD; the associations between WIQ scores and atherosclerotic burden (i.e. PvD); and whether WIQ scores identify patients with an increased risk for new CV events.

Methods {#sec2-2048004019841971}
=======

Patient population {#sec3-2048004019841971}
------------------

The design of the REBUS (The RElevance of Biomarkers for future risk of thromboembolic events in UnSelected post-MI patients)^[@bibr17-2048004019841971]^ study has been previously published. The REBUS study was a prospective observational study of patients with recent MI (NCT01102933, ClinicalTrials.gov)^[@bibr17-2048004019841971]^ with both Non-ST-elevation (NSTEMI) or ST-elevation (STEMI) admitted to the acute coronary care unit at the Department of Cardiology, Uppsala University Hospital, during 2010--2012. The patients were included 3--5 days after the index MI and followed-up for two years. The first visit was performed at 2--3 weeks after inclusion in the study.

The composite CV endpoint consisted of all-cause death, new MI, stroke, and congestive heart failure (CHF), after the usual definition previously described.^[@bibr17-2048004019841971]^ All participants signed an informed consent form, and the study was approved by the local ethical committee and conducted in accordance with the ethical principles of the Declaration of Helsinki (Dnr 2009/210).

Evaluation of atherosclerosis {#sec4-2048004019841971}
-----------------------------

Atherosclerosis in the vascular beds was categorized as previously described in detail.^[@bibr18-2048004019841971]^ In summary: Coronary artery disease (CAD) was classified based on findings from coronary angiography performed during hospitalisation for the index MI. The patients were categorized into two groups: (a) normal findings or (b) abnormal findings, including all stenosis or occlusions.The carotid arteries were examined on both sides with duplex ultrasonography three months after the index event. The patients were divided into two groups after examination: (a) normal findings and (b) abnormal findings, including all atherosclerotic lesions (plaques, stenosis, or occlusions) and patients with a previous history of carotid endarterectomy.PAD was evaluated in all patients, 2--3 weeks after the index MI, by measuring the ABI at rest. PAD was defined as an abnormal ABI score (\<0.9 or \>1.4) on at least one leg.

*Poly vascular disease* (*PvD*) was defined as abnormal findings, as defined above, in all three examined arterial beds (i.e. coronary, carotid, and lower extremity).

Walking Impairment Questionnaire {#sec5-2048004019841971}
--------------------------------

In this study, we used a revised version of the WIQ, adapted and validated for the metric system, and translated to Swedish.^[@bibr12-2048004019841971],[@bibr19-2048004019841971]^ The questionnaire is included in the Appendix.

Participants were distributed the WIQ forms at the follow-up visit 2--3 weeks after inclusion and completed in privacy at the hospital.

The WIQ score contains three domains measuring important factors of walking impairment: walking distance, walking speed, and ability to climb stairs. All subdomains are graded from 0 (worst/inability) to 4 (best/without limitations). *Walking distance* score assess the degree of difficulty in walking a specific distance the last week, ranging from walking 15 to 500 meters or five blocks. In the walking *speed scores*, the patients are asked to assess the degree of difficulty of walking a block in a specific speed (walking slowly to jogging). The *stair climbing* score reports the difficulty in climbing a specific number of flights of stairs (one to three).

Individual scores are calculated stepwise: first the graded scale is multiplied by a pre specified weight for each question. Second, the products are summed and then divided by the maximum possible score, ranging from 0 (when the patient is unable to perform any of the tasks) to a maximum of 100 in all questions. The individual scores were divided into quartiles and our main analyses were comparing the lowest (worst) versus the highest (best) quartile.

Statistics {#sec6-2048004019841971}
----------

Data were presented as means and standard deviations for continuous variables and as numbers and percentages for categorical variables. All continuous variables were normally distributed.

Scores for each subdomain of the WIQ were determined and divided into quartiles. Given the large number of patients with a WIQ distance score of 100, we grouped participants scoring at both third and fourth quartiles into one group (third/fourth quartile). The correlation between all three WIQ questions was examined with the Spearman rank correlation coefficient.

A linear regression model was used for comparisons of age and BMI at baseline between WIQ quartiles. For other baseline variables, Fisher's exact test was used for comparisons of characteristics between WIQ quartiles.

Univariate associations and adjusted associations between atherosclerotic burden and WIQ score quartiles were assessed with logistic regression models. In Model 1, the adjusted variables were age and gender and in Model 2, age, gender, CHF, atrial fibrillation, and diabetes. Results from logistic regression models are presented as estimated odds ratio (OR), comparing the lowest (worst) quartile to the highest (best), with 95% confidence intervals (CIs) and p-values.

Proportional hazards Cox regression models were used to compare differences in rates of CV composite endpoint, occurring between 2--3 weeks after index MI and 2 years after, across WIQ score quartiles. Results from Cox regression models are presented as estimated hazard ratio (HR), comparing the lowest (worst) quartile to the highest (best), with 95% CIs and p-values.

All statistical tests and CIs were two sided, and a statistically significant result was declared if the p-value \< 0.05. All analyses were performed with the statistical program package, SPSS Statistics 22 and SAS 9.4 (SAS Institute, Inc., Cary, NC).

Results {#sec7-2048004019841971}
=======

The present study included the 263 patients, who completed the WIQ questionnaire 2--3 weeks after the index MI and who had all three arterial beds (coronary, carotid, and peripheral arteries) evaluated.

[Tables 1](#table1-2048004019841971){ref-type="table"} to [3](#table3-2048004019841971){ref-type="table"} list the baseline characteristics by WIQ *walking distance*, *speed*, and *stair climbing* quartiles. The cohort consisted of 66 (25.1%) women and 197 (74.9%) men, 125 (47.5%) had an STEMI and 138 (52.5%) an NSTEMI as index event.

###### 

Clinical characteristics for WIQ *walking distance* at visit 1, 2--3 weeks after index MI.

![](10.1177_2048004019841971-table1)

  Mean 73.2 (SD 35.01)                                                    Q1 (0--48.59)   Q2 (48.6--99.99)   Q3--4 (100)   p-Value^[a](#table-fn2-2048004019841971){ref-type="table-fn"}^
  ----------------------------------------------------------------------- --------------- ------------------ ------------- ----------------------------------------------------------------
  N (%) = 263                                                             65              60                 138           
  Age (mean, SD)                                                          72.4 (10.6)     66.5 (10.8)        65.6 (9.3)    0.0001
  Female                                                                  24 (36.9)       23 (38.3)          19 (13.8)     0.0001
  Male                                                                    41 (63.1)       37 (61.7)          119 (86.2)    
  BMI (SD)                                                                26.9 (4.8)      27.1 (4.0)         26.5 (3.8)    0.378
  Smoking, current                                                        18 (27.7)       22 (36.7)          29 (21.0)     0.085
  NSTEMI                                                                  34 (52.3)       33 (55.0)          71 (51.4)     0.9
  STEMI                                                                   31 (47.7)       27 (45.0)          67 (48.6)     
  Diabetes                                                                16 (24.6)       5 (8.3)            14 (10.1)     0.008
  Hypertension                                                            45 (69.2)       26 (43.3)          72 (52.2)     0.011
  Previous MI                                                             21 (32.2)       11 (18.3)          19 (13.8)     0.008
  Previous stroke                                                         7 (10.8)        2 (3.3)            5 (3.6)       0.079
  Previous PAD                                                            4 (6.2)         2 (3.3)            2 (1.4)       0.188
  Previous CHF                                                            15 (23.1)       0                  5 (3.6)       0.0001
  Atrial fibrillation                                                     12 (18.5)       5 (8.3)            7 (5.1)       0.008
  Renal disease                                                           8 (12.3)        1 (1.7)            1 (0.7)       0.0001
  LV-EF, N = 224^[b](#table-fn3-2048004019841971){ref-type="table-fn"}^   58              48                 118           0.012
  Normal function                                                         34 (58.6)       36 (75.0)          6 (12.5)      
  Mildly impaired                                                         9 (15.5)        6 (12.5)           16 (13.6)     
  Moderately impaired                                                     15 (25.9)       6 (12.5)           8 (6.8)       

MI: myocardial infarction; PAD: peripheral artery disease; CHF: congestive heart failure; LV-EF: left ventricular ejection function.

^a^p-Value for trend.

^b^The echocardiogram was performed in 224 out of the 263 patients after the index event, before discharge.

###### 

Clinical characteristics for WIQ *speed* at visit 1, 2--3 weeks after index MI.

![](10.1177_2048004019841971-table2)

  Mean 40.5 (SD 23.5)                                                     Q1 (0--30.29)   Q2 (30.3--35.89)   Q3 (35.9--56.49)   Q4 (56.5--100)   p-Value^[a](#table-fn5-2048004019841971){ref-type="table-fn"}^
  ----------------------------------------------------------------------- --------------- ------------------ ------------------ ---------------- ----------------------------------------------------------------
  N (%) = 263                                                             65              66                 51                 81               
  Age (mean, SD)                                                          70.8 (11.5)     67.4 (10.9)        64.9 (9.6)         65.4 (8.8)       0.001
  Female                                                                  25 (38.5)       23 (34.8)          12 (23.5)          6 (7.4)          0.0001
  Male                                                                    40 (61.5)       43 (65.2)          39 (76.5)          75 (92.6)        
  BMI (SD)                                                                26.8 (4.8)      26.9 (3.4)         27.5 (4.4)         26.5 (3.6)       0.358
  Smoking, current                                                        16 (24,6)       21 (31.8)          19 (37.3)          13 (16.0)        0.086
  NSTEMI                                                                  35 (53.8)       33 (50.0)          29 (56.9)          41 (50.6)        0.869
  STEMI                                                                   30 (46.2)       33 (50.0)          22 (43.1)          40 (49.4)        
  Diabetes                                                                12 (18.5)       9 (13.6)           6 (11.8)           8 (9.9)          0.487
  Hypertension                                                            38 (58.5)       34 (51.5)          29 (56.9)          42 (51.9)        0.804
  Previous MI                                                             17 (26.2)       8 (12.1)           11 (21.6)          15 (18.5)        0.228
  Previous stroke                                                         8 (12.3)        5 (7.6)            0                  1 (1.2)          0.006
  Previous PAD                                                            3 (4.6)         2 (3.0)            3 (5.9)            0                0.214
  Previous CHF                                                            12 (18.5)       2 (3.0)            2 (3.9)            4 (4.9)          0.002
  Atrial fibrillation                                                     10 (15.4)       5 (7.6)            3 (5.9)            6 (7.4)          0.241
  Renal disease                                                           6 (9.2)         1 (1.5)            1 (2.0)            2 (2.5)          0.07
  LV-EF, N = 224^[b](#table-fn6-2048004019841971){ref-type="table-fn"}^   53              62                 46                 63               0.033
  Normal function                                                         34 (64.2)       41 (66.1)          36 (78.3)          53 (84.4)        
  Mildly impaired                                                         6 (11.3)        12 (19.4)          6 (13.0)           7 (11.1)         
  Moderately impaired                                                     13 (24.5)       9 (14.5)           4 (8.7)            3 (4.8)          

MI: myocardial infarction; PAD: peripheral artery disease; CHF: congestive heart failure; LV-EF: left ventricular ejection function.

^a^p-Value for trend.

^b^The echocardiogram was performed in 224 out of the 263 patients after the index event, before discharge.

###### 

Clinical characteristics for WIQ *stair climbing* at visit 1, 2--3 weeks after index MI.

![](10.1177_2048004019841971-table3)

  Mean 50.5 (SD 36.6)                                                     Q1 (0--16.69)   Q2 (16.7--49.99)   Q3 (50.0--87.49)   Q4 (87.5--100)   p-Value^[a](#table-fn8-2048004019841971){ref-type="table-fn"}^
  ----------------------------------------------------------------------- --------------- ------------------ ------------------ ---------------- ----------------------------------------------------------------
  N (%) = 263                                                             48              76                 57                 82               
  Age (mean, SD)                                                          72.2 (11.2)     66.3 (11.3)        66.4 (10.1)        65.5 (8.4)       0.003
  Female                                                                  18 (37.5)       21 (27.6)          17 (29.8)          10 (12.2)        0.007
  Male                                                                    30 (62.5)       55 (72.4)          40 (70.2)          72 (87.8)        
  BMI (SD)                                                                27.1 (4.7)      26.8 (4.4)         26.7 (4.0)         26.4 (3.4)       0.364
  Smoking, current                                                        8 (16.7)        17 (22.4)          17 (29.8)          27 (32.9)        0.38
  NSTEMI                                                                  24 (50.0)       45 (59.2)          31 (54.4)          38 (46.3)        0.42
  STEMI                                                                   24 (50)         31 (40.8)          26 (45.6)          44 (53.7)        
  Diabetes                                                                10 (20.8)       9 (11.8)           8 (14.0)           8 (9.8)          0.331
  Hypertension                                                            32 (66.7)       40 (52.6)          27 (47.4)          44 (53.7)        0.245
  Previous MI                                                             9 (18.8)        18 (23.7)          11 (19.3)          13 (15.9)        0.667
  Previous stroke                                                         6 (12.5)        4 (5.3)            3 (5.3)            1 (1.2)          0.054
  Previous PAD                                                            4 (8.3)         1 (1.3)            2 (3.5)            1 (1.2)          0.098
  Previous CHF                                                            9 (18.8)        4 (5.3)            3 (5.3)            4 (4.9)          0.016
  Atrial fibrillation                                                     10 (20.8)       7 (9.2)            4 (7.0)            3 (3.7)          0.011
  Renal disease                                                           4 (8.3)         4 (5.3)            1 (1.8)            1 (1.2)          0.152
  LV-EF, N = 224^[b](#table-fn9-2048004019841971){ref-type="table-fn"}^   39              70                 51                 64               0.258
  Normal function                                                         22 (56.4)       52 (74.3)          41 (80.4)          49 (76.6)        
  Mildly impaired                                                         9 (23.1)        9 (12.9)           6 (11.8)           7 (10.9)         
  Moderately impaired                                                     8 (20.5)        9 (12.9)           4 (7.8)            8 (12.5)         

MI: myocardial infarction; PAD: peripheral artery disease; CHF: congestive heart failure; LV-EF: left ventricular ejection function.

^a^p-Value for trend.

^b^The echocardiogram was performed in 224 out of the 263 patients after the index event, before discharge.

Significant correlations were observed between the WIQ scores, *walking distance* versus *speed* (r = 0.61, p \< 0.0001), *walking distance* versus *stair climbing* (r = 0.39, p \< 0.0001), and between *walking speed* and *stair climbing* (r = 0.52, p \< 0.0001).

Baseline characteristics in relation to WIQ score {#sec8-2048004019841971}
-------------------------------------------------

There was an association between increased age and a higher proportion of women in all domains with the highest age and the larger proportion of women in the lowest (worst) quartile compared to the highest (best) quartile. The proportion of current smokers and the distribution of index type of MI (STEMI/NSTEMI) was similar comparing the lowest (worst) and highest (best) quartiles in all score domains.

*Distance score* ([Table 1](#table1-2048004019841971){ref-type="table"}): There was an association between patients with diabetes (p = 0.008), previous MI (p = 0.008), and previous CHF (p = 0.001) with a higher proportion in the lowest (worst) quartile. This was also true for atrial fibrillation, renal failure, and of impaired LV-EF after the index, event.

*Speed score* ([Table 2](#table2-2048004019841971){ref-type="table"}): There was an association between previous stroke (p = 0.006) and previous CHF (p = 0.002), with a higher proportion in the lowest (worst) quartile. The same was true for renal failure and of impaired LV-EF.

*Stair climbing score* ([Table 3](#table3-2048004019841971){ref-type="table"}): There was an association between previous CHF (p = 0.016) and atrial fibrillation with a higher proportion in the lowest (worst) quartile.

Medical treatment and WIQ score {#sec9-2048004019841971}
-------------------------------

The adherence to guideline recommended medical treatment for secondary prevention was high; at visit 1, 99.2% were treated with antiplatelet drugs, 92.8% with statins, 91.6% with beta blockers, and 81.7% were treated with angiotensin converter enzyme inhibitor or angiotensin II receptor blocker. The adherence to medical treatment persisted during follow-up at two years.

Atherosclerotic burden and WIQ score {#sec10-2048004019841971}
------------------------------------

Two hundred and fifty-seven (97.7%) out of the 263 patients had an abnormal coronary angiogram. Fifty-two (19.8%) patients had an abnormal ABI and 136 (51.7%) patients had an abnormal carotid duplex. PvD, with three affected arterial beds, was found in 34 (12.9%) patients. The proportion of patients with PAD and PvD was higher in the lowest (worst) quartile for all WIQ scoring domains ([Figure 1(a) and (b)](#fig1-2048004019841971){ref-type="fig"}).

![(a) Peripheral artery disease (PAD) and (b) polyvascular disease (PvD) show distribution of WIQ score with the lowest (worst) score to the left and the highest (best) score to the right in each WIQ question. Given the large number of patients with a WIQ distance score of 100, we grouped participants scoring at both third and fourth quartiles into one group (third/fourth quartile).](10.1177_2048004019841971-fig1){#fig1-2048004019841971}

*Distance score*: In patients with PAD, there was an association between scoring the lowest (worst) quartile relative to the highest (best) quartile, after adjustment for age, gender, CHF, atrial fibrillation, and diabetes (fully adjusted), OR 3.9 (95% CI 1.6--9.2, p = 0.002) ([Figure 2(a)](#fig2-2048004019841971){ref-type="fig"}). Similar results were found in patients with PvD with an association between scoring the lowest (worst) score relative to highest (best) score after full adjustment, OR 5.4 (95% CI 1.8--16.1, p = 0.002) ([Figure 2(b)](#fig2-2048004019841971){ref-type="fig"}).

![The risk of atherosclerotic disease in patients scoring in the lowest (worst) group/quartile. (a) Peripheral artery disease (PAD) and (b) polyvascular disease (PvD). Model 1: adjusted for age and gender. Model 2: adjusted for age, gender, congestive heart failure, atrial fibrillation, and diabetes.](10.1177_2048004019841971-fig2){#fig2-2048004019841971}

*Speed score*: The lowest (worse) quartile was associated with PAD relative to the highest (best) quartile after full adjustment OR 3.2 (95% CI 1.2--8.6, p = 0.022) ([Figure 2(a)](#fig2-2048004019841971){ref-type="fig"}). In patients with PvD, the association with the lowest (worst) quartile relative to the highest (best) remained after full adjustment OR 7.4 (95% CI 1.5--36.5, p = 0.015) ([Figure 2(b)](#fig2-2048004019841971){ref-type="fig"}).

*Stair climbing score*: In contrast to the distance and speed score, the association between PAD and the lowest (worst) quartile relative to highest (best) quartile did not persist after full adjustment ([Figure 2(a)](#fig2-2048004019841971){ref-type="fig"}). In patients with PvD, the association with the lowest (worst) quartile attenuated after full adjustment ([Figure 2(b)](#fig2-2048004019841971){ref-type="fig"}).

Cardiovascular events and WIQ score {#sec11-2048004019841971}
-----------------------------------

Forty-three (16.3%) out of 263 patients reached a composite CV endpoint during the two-year follow-up. Six (2.3%) of these patients died. Twenty-one (8.0%) had a new MI, 17 (6.5%) were hospitalized for CHF, and 6 (2.3%) had a stroke.

*Distance score* ([Figure 3](#fig3-2048004019841971){ref-type="fig"}): In the fully adjusted model, there was no association between lowest (worst) score and risk for the composite CV endpoint, compared to the highest (best) score, HR 1.9 (95% CI 0.8--4.5, p = 0.118).

![The risk of composite cardiovascular endpoint at 24 months if scoring in the lowest (worst) WIQ group. Model 1: adjusted for age and gender. Model 2: adjusted for age, gender, congestive heart failure, atrial fibrillation, and diabetes.](10.1177_2048004019841971-fig3){#fig3-2048004019841971}

*Speed score* ([Figure 3](#fig3-2048004019841971){ref-type="fig"}): We found no association with the lowest (worst) score relative to the highest (best) score and the composite endpoint after full adjustment, HR 1.8 (95% CI 0.8--4.6, p = 0.166).

*Stair climbing score* ([Figure 3](#fig3-2048004019841971){ref-type="fig"}): Patients with the lowest (worst) score had a higher risk for the composite CV endpoint compared to the highest (best) score, HR 5.3 (95% CI 1.5--19.0, p = 0.011) in the fully adjusted model.

Discussion {#sec12-2048004019841971}
==========

In this prospective observational study of patients with recent MI using the self-assessing WIQ, we found that PvD, as well as PAD manifested as abnormal ABI, was associated with the lowest (worst) score categories in both *distance and speed*, even after adjustment for age and sex and comorbidities. Furthermore, the majority of patients with PvD were found in the lowest (worst) score in *stair climbing*.

Overall, patients in the lowest (worst) score had an increased risk for a CV outcome, even after full adjustment for other comorbidities.

The WIQ questionnaire has been validated against objective measures of walking ability in several studies,^[@bibr10-2048004019841971][@bibr11-2048004019841971]--[@bibr12-2048004019841971],[@bibr20-2048004019841971],[@bibr21-2048004019841971]^ but only a few studies have examined the usefulness of WIQ scores for predicting outcomes.^[@bibr15-2048004019841971],[@bibr16-2048004019841971]^ A limited number of studies have evaluated the WIQ in patients without PAD with varying results,^[@bibr13-2048004019841971],[@bibr14-2048004019841971],[@bibr16-2048004019841971]^ but so far no study has evaluated WIQ in a population with recent MI.

The different WIQ domain scores have in the present study somewhat different implications, in line with what has also been reported by others.^[@bibr14-2048004019841971],[@bibr22-2048004019841971]^ The *walking distance and speed scores* seem better at identifying patients with PAD and those with PvD even after adjustment for age, sex, and comorbidities closely associated with CV disease, such as diabetes and CHF.

There is a strong correlation between all of the three WIQ domains, especially *distance and speed scores* and conditions that deteriorate walking ability could consequently be of importance. The importance of heart failure in this context is difficult to interpret. Multiple pathways are linking PAD and heart failure, with several risk factors in common such as diabetes and hypertension^[@bibr23-2048004019841971],[@bibr24-2048004019841971]^ where elevated afterload, due to hypertension and elevated aortic stiffness, in the end could lead to heart failure.^[@bibr23-2048004019841971],[@bibr24-2048004019841971]^ Also, PAD associated with overt atherosclerosis involving coronary atherosclerosis increases the risk for heart failure.^[@bibr25-2048004019841971]^ Several studies and a meta-analysis also show that the presence of PAD in patients with heart failure is an independent predictor of hospitalizations and mortality.^[@bibr26-2048004019841971],[@bibr27-2048004019841971]^ The *stairs score* has also been suggested as a surrogate marker of the patients' cardio-pulmonary capacity and consequently prognosis.^[@bibr14-2048004019841971],[@bibr28-2048004019841971]^ In this study, 20 (7.6%) patients suffered from CHF at inclusion with significantly more patients in the lowest (worst) score in all three WIQ domains. The echocardiography after the index event also showed a larger proportion of impaired left ventricular ejection fraction in the *walking distance* and *speed score*s and among these patients significantly more in the lowest (worst) score, but surprisingly not in the *stairs score*. This could have influenced the results.

In patients with PAD, the WIQ score predicts future CV events and mortality;^[@bibr15-2048004019841971],[@bibr16-2048004019841971]^ Schiano et al.^[@bibr15-2048004019841971]^ showed an association between CV events and *speed and stair climbing* score and a study from Gardner et al.^[@bibr22-2048004019841971]^ showed association between *stair climbing* score with all-cause mortality. Jain et al.^[@bibr14-2048004019841971]^ monitored patients with and without PAD and found that in patients with PAD those with the lowest (worst) baseline quartile of WIQ *stair climbing* score had an increased all-cause and CV mortality, as compared to those in the highest (best) baseline quartile. In patients without PAD, there were no such association. In the only study to our knowledge evaluating WIQ in coronary angiography patients, Nead et al.^[@bibr13-2048004019841971]^ found that any reported deficit score (i.e. score \<100% vs. 100%) in all three WIQ domains had a significantly increased risk of both all-cause and CV mortality. Interestingly, they also showed that WIQ score, when added to established risk models, significantly improved risk discrimination and reclassification. In our study, the *stairs climbing score* had a greater association with CV events/mortality than *walking distance and speed scores*.

The patients in our cohort were all well medically treated, with a high proportion of guideline-recommended secondary prevention drug therapy, with no major differences between the lowest (worst) or highest (best) quartiles and remaining high adherence after two years of follow-up.

The mortality in the present cohort is low, only 6 (2.3%) patients out of 263 died during the two-year follow-up, in comparison with previously published studies in PAD-populations^[@bibr8-2048004019841971]^ and post-MI patients.^[@bibr29-2048004019841971]^ A partial explanation might be the high prevalence of guideline-recommended secondary prevention drugs in our cohort. In post-MI patients, the prevalence of these drugs is generally higher^[@bibr29-2048004019841971]^ than in many PAD-populations where the secondary prevention is less prominent.^[@bibr8-2048004019841971],[@bibr19-2048004019841971],[@bibr30-2048004019841971]^ In the present study including additional visits, discussing the importance of secondary prevention may have contributed to the high adherence compared to clinical praxis.

The present study is the first to evaluate the WIQ in a cohort of patients early after an MI and the results suggest that the questionnaire may be useful, to identify patients with a widespread atherosclerotic disease associated with an increased CV risk.

Limitations of the study {#sec13-2048004019841971}
------------------------

The study is based on one center, and the sample size of this study's patient cohort suggests a need for larger prospective studies to evaluate the WIQ score in patients with recent MI and a longer time for follow-up would also be desired. In this study, we used a combination of morphological and functional methods for the identification of atherosclerosis in the different arterial bed instead of using the same type of method, which might have influenced the results.

Conclusion {#sec14-2048004019841971}
==========

In this prospective observational study of patients with recent MI and evaluation of the WIQ score, we found that additional atherosclerotic burden with PAD and patients with PvD, respectively, was associated with scoring in the lowest (worst) score in both *walking distance and speed* scores, even after adjustment for age and sex and comorbidities. Furthermore, the majority of patients with PvD were found in the lowest (worst) score in *stair climbing*, and patients with the lowest (worst) score were associated with an increased risk for new CV events, even after adjustment for other comorbidities. The results indicate, although our patients were in recovery from his or her MI, that the WIQ score give valuable information to assess patients early after an MI for a more widespread atherosclerotic burden associated with a higher risk.
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